Yes. Travoprost is typically instilled in each affected eye once daily. The dosing schedule remains the same regardless of whether one or both eyes are treated.
Mild redness is common and usually resolves within a short period. If redness persists, becomes painful, or is accompanied by vision changes, contact your eye-care professional promptly.
Remove contact lenses before instillation and wait at least 15 minutes before reinserting them. Some lens materials may absorb the medication, potentially causing discoloration or reduced lens comfort.
After opening, the bottle should be used within 6 weeks. Even if the solution appears clear, potency may decline beyond this period.
Travoprost can be combined with beta-blocker or carbonic anhydrase inhibitor drops for additive IOP reduction. Coordination with an eye-care professional ensures appropriate timing and monitoring.
Evening dosing aligns with the medication’s peak effect during nighttime, when IOP naturally rises. This timing also reduces the likelihood of transient blurred vision interfering with daytime activities.
Severe eye pain, swelling, intense redness, or vision loss may indicate an allergic response. Seek immediate medical attention if these symptoms occur.
Travoprost’s systemic absorption is minimal, and it generally does not impact blood pressure. However, patients on systemic prostaglandin-related therapies should discuss potential interactions with their clinician.
Travoprost bottles are permitted in hand luggage for personal use. Keep the medication in its original packaging, and ensure it is stored at room temperature, away from excessive heat or cold during travel.
All prostaglandin analogs lower IOP by increasing uveoscleral outflow, but they differ slightly in receptor affinity, side-effect profiles, and preservative formulations. Choice of agent depends on individual response and tolerance.
This article covers Travoprost, available as a generic medication and marketed under brand names such as Travatan. Travoprost is a prostaglandin analog used in eye care to lower intra-ocular pressure (IOP). It is supplied as a 0.004 % ophthalmic solution in a single-use bottle. In the United Kingdom, Travoprost is a prescription-only medicine regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Travoprost belongs to the prostaglandin-F₂α analog class. After topical application to the eye, it is hydrolysed to its active acid form, which binds to prostaglandin FP receptors in the ciliary muscle. This triggers remodeling of the extracellular matrix and relaxes the trabecular meshwork, leading to increased uveoscleral outflow of aqueous humour. The result is a reduction in intra-ocular pressure, helping to protect the optic nerve from pressure-related damage.
Travoprost is approved in the UK for the following indications:
These conditions are characterised by elevated intra-ocular pressure that can lead to progressive optic nerve damage and visual field loss. Travoprost is prescribed when IOP reduction is needed to preserve vision.
Travoprost is appropriate for adult patients diagnosed with POAG or OHT who require pharmacologic IOP reduction. It is commonly chosen for patients who need a convenient once-daily regimen.
Travoprost has a low potential for systemic drug interactions, but ocular pharmacologic interactions may occur:
If you have specific health conditions, dosing may need adjustment. Always follow the prescribing clinician’s instructions.
Regular intra-ocular pressure checks are essential to determine therapeutic effectiveness:
This article provides educational information about Travoprost and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
